Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis Meeting Abstract

  

Authors:	Ajufo, H.; Bewersdorf, J. P.; Harrison, C.; Palandri, F.; Mascarenhas, J.; Palmer, J. M.; Gerds, A. T.; Kiladjian, J. J.; Derkach, A.; Rampal, R.; Buckley, S.; Roman-Torres, K.
Abstract Title:	Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis
Meeting Title:	2023 ASCO Annual Meeting
Journal Title:	Journal of Clinical Oncology
Volume:	41
Issue:	16 Suppl.
Meeting Dates:	2023 Jun 2-6
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2023-06-01
Language:	English
DOI:	10.1200/JCO.2023.41.16_suppl.7018
PROVIDER:	EBSCOhost
PROVIDER:	cinahl
DOI/URL:	https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,shib&db=cin20&AN=164014753&authtype=sso&custid=s2915669&site=ehost-live&scope=site&custid=s2915669
Notes:	Meeting abstract: 7018 -- Meeting also presented virtually -- Source: Cinahl

https://synapse.mskcc.org/synapse/works/has_related_data_chk/209488